ClinicalTrials.gg
WithdrawnNCT04100720Updated May 11, 2026

Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation

An interventional study of Cardiovalve Transfemoral Tricuspid Valve in Tricuspid Regurgitation, sponsored by Cardiovalve Ltd.. Withdrawn at 3 sites in United States. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Cardiovalve Ltd. · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
COVID Impact

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Enrollment
42nd of 42
0 · median 63
Started
2024
with 7 others
No phase
39 of 60
18 open now
Registered
20th of 60
by date

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 42nd largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2024, is one of 39 with no phase, and was the 20th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This study is to evaluate the safety and technical performance of the Cardiovalve Transfemoral System for tricuspid valve replacement. Data collected in the clinical study will include 30-day safety and performance of the device and delivery system, and long-term clinical outcomes over a follow-up of 5 years.

Read the detailed description

The Cardiovalve Transfemoral System for tricuspid valve replacement

Data collected in the clinical study will include 30-day safety and performance of the device and delivery system, and long-term clinical outcomes over a follow-up of 5 years.

03

Conditions studied

  • Tricuspid Regurgitation
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is 85 ≥ Age ≥ 18 years
  2. Participant has severe, symptomatic tricuspid regurgitation (TR) ≥ 3+ based upon echocardiography, as assessed by Independent core laboratory
  3. Participant is (NYHA) Class II-IVa
  4. Participant has (LVEF) ≥ 35%
  5. Participant distance of 6 minute walk test (6MWT) ≥ 60 m
  6. Participant adequately treated based upon medical standards, including for coronary artery disease, mitral regurgitation and Guideline Directed Medical Therapy (GDMT) for heart failure for at least 30-days prior to index procedure.
  7. Acceptable by the site "Heart Team" including an interventional cardiologist, cardiothoracic surgeon, heart failure cardiologist and recommended as a candidate for the Cardiovalve System
  8. Participant approved by the Subject Screening Committee

Exclusion criteria

Exclusion Criteria:

  1. Known significant intracardiac shunt (e.g. septal defect) or congenital structural heart disease (PFO's without significant shunts are allowed)
  2. Significant coronary artery disease requiring treatment
  3. Primary tricuspid disease (e.g. rheumatic, myxomatous degeneration, tricuspid valve prolapse)
  4. Severe right ventricular failure per ASE guidelines1
  5. Systolic pulmonary arterial pressure > 65 mmHg as assessed by transthoracic echocardiography
  6. Presence of any known life threatening non-cardiac disease that will limit the subject's to less than one year
  7. Cerebrovascular event (stroke, ) within the past 3 months
  8. Active endocarditis or history of mitral/tricuspid endocarditis within the last 12 months
  9. Patient has significant left sided valvular heart disease which requires treatment (e.g. mitral regurgitation or stenosis, and aortic regurgitation or stenosis)
  10. Documented primary coagulopathy or disorder, including thrombocytopenia (absolute platelet count \<90k)
  11. Documented evidence of significant renal dysfunction (\<30 ml/min/1.73m2) or on any form of dialysis at time of screening within the last 4 weeks
  12. or known allergy to device's components, to anti-coagulation therapy with vitamin K antagonists or to contrast media that cannot be adequately premedicated
  13. Patients unsuitable for implantation because of thrombosis of the lower venous system or presence of a vena cava filter
  14. The patient has contraindication against a transesophageal echo (TEE) during the procedure
  15. Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days)
  16. Hepatic insufficiency (MELD > 10)
  17. Female patient of
  18. Psychiatric or behavioral disease including known alcohol or drug abuser that is likely to impair compliance with protocol
  19. Requirement for Antibiotic Treatment within the last 48 hours
  20. Cardiac Anatomy deemed not suitable for the Cardiovalve Implant
  21. Surgical or interventional procedure planned within 30 days prior to index procedure
  22. UNOS Status 1 heart transplant or prior orthotropic heart transplantation.
  23. Any prior Tricuspid valve surgery or transcatheter Tricuspid valve procedure
  24. Modified Rankin Scale > 4 disability
  25. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within one month prior to index procedure
  26. Need for any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of index procedure
  27. Currently participating in an drug or another device study which has not reached its primary endpoint
  28. Patient (or legal guardian) unable or unwilling to provide written, before study enrollment
  29. Chronic oral or other condition that could impair healing response (e.g. cardiac sarcoidosis or other chronic inflammatory disease).
  30. Acutely decompensated heart failure (i.e. hemodynamically unstable or requiring IV inotrope ) at the time of screening
  31. Severe or continuous use of home oxygen
  32. Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
  33. Aortic or pulmonic valve disease requiring surgery
  34. Venous peripheral anatomy unsuitable for implant delivery
  35. Chronic anemia ( \< 9)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cardiovalve Transfemoral Tricuspid Valve

    Replacement (Implant) delivered through a transfemoral access

    Device: Cardiovalve Transfemoral Tricuspid Valve

Interventions

  • DeviceCardiovalve Transfemoral Tricuspid Valve

    The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation

06

What researchers measure

Primary outcomes

  1. 1. Primary Performance Endpoint - Technical Success of Cardiovalve Delivery and Function in each participant

    Cardiovalve Technical Success defined as: I Successful access, delivery and retrieval of the delivery system; II Successful deployment of correct positioning of the first intended implant; III Freedom from emergency surgery or reintervention related to the device or access procedure without any procedural mortality, stroke, and device dysfunction at 30-day follow-up.

    Time frame: 30 Days

  2. Primary Performance Endpoint - Clinical Performance - Reduction in Tricuspid Regurgitation severity measured using Echocardiography and compared to baseline

    Cardiovalve Clinical Performance will be evaluated as: I The reduction in degree of tricuspid regurgitation measured immediately after the procedure compared to baseline; II The reduction in degree of tricuspid regurgitation measured at the time of discharge or 7 days post procedure, whichever comes first, in comparison with baseline Tricuspid Regurgitation is measured using Echocardiography and is graded based on degree of severity using grading conventions from 0 to 4+. 0 = absent 1. = mild 2. = moderate 3. = moderate to severe 4. = severe

    Time frame: 30 Days

  3. Primary Safety Endpoint (Patient Based) Participants Implanted without Major Device Related Adverse Events through thirty days

    The ability of the Cardiovalve to be implanted without Major Device Related Adverse Events through thirty (30) days including: I Death (Cardiovascular mortality vs non-cardiovascular); II Reintervention (operative or transcatheter) due to progressive or recurrent TR or device related complications; III Disabling stroke; IV Myocardial infarction (MVARC definition); V Major access site and vascular complications; VI Fatal or life-threatening bleeding (MVARC Type III-V); VII Arrhythmia and conduction disorder requiring permanent pacing; VIII Right coronary artery occlusion requiring intervention; IX Cardiac tamponade, X Renal failure requiring dialysis

    Time frame: 30 Days

Secondary outcomes

  1. Secondary Performance Endpoint - Tricuspid Regurgitation Severity

    Tricuspid Regurgitation is measured using Echocardiography and is graded based on degree of severity using grading conventions from 0 to 4+. 0 = absent 1. = mild 2. = moderate 3. = moderate to severe 4. = severe

    Time frame: 30 days, 3 months, 6 months

  2. Secondary Performance Endpoint - Cusp Insufficiency

    Cusp Insufficiency: Change in the degree of the cusp insufficiency as assessed with echocardiography (ordinal) from a higher to a lower value

    Time frame: 30 days, 3 months, 6 months

  3. Secondary Performance Endpoint - Unrestricted Movement of Cusps

    Unrestricted Movement of Cusps: the percentage of medical devices with unrestricted movement of cusps after implantation as assessed with echocardiography

    Time frame: 30 days, 3 months, 6 months

  4. Secondary Performance Endpoint - New York Heart Association (NYHA) functional class

    NYHA function class I - IV; Higher functional class represents more severe symptoms of heart failure NYHA Classification - The Stages of Heart Failure: 1. Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. 2. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. 3. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest. 4. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

    Time frame: 30 days, 3 months, 6 months

  5. Secondary Performance Endpoint - 6 minute walk test

    6 minute walk test distance (meters)

    Time frame: 30 days, 3 months, 6 months

  6. Secondary Performance Endpoint - Kansas City Cardiomyopathy Questionnaire

    Kansas City Cardiomyopathy Questionnaire (KCCQ) - 23 subjective quality of life questions. Assessed before and after implantation. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. There are 3 subscales: Symptom Burden - range 0-100; Physical Limitation - range 0-100; Quality of Life - range 0-100; The total KCCQ score represents the mean (average) of the three subscale scores.

    Time frame: 30 days, 3 months, 6 months

07

Study locations

3 sites
  • Northwestern University / Bluhm Cardiovascular Institute
    Chicago, Illinois 60611, United States
  • Columbia University Medical Center / NYPH
    New York, New York 10032, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2024; primary completion for Dec 2025, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2019
First posted
Sep 24, 2019
StartEst.
Feb 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2030
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04100720
Lead sponsor
Cardiovalve Ltd.
Collaborators
Cardiovascular Research Foundation, New York
Responsible party
Sponsor
First posted
Sep 24, 2019
Start date
Feb 2024 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion